Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence

Ruth Etzioni, Donna P. Ankerst, Noel S. Weiss, Lurdes Y.T. Inoue, Ian M. Thompson

Research output: Contribution to journalComment/debate

38 Citations (Scopus)

Abstract

Prostate-specific antigen velocity (PSAV) is one of the oldest concepts in PSA screening, yet today it is one of the most controversial. Publication of a wide range of studies with different designs, study populations, and results has fueled uncertainty about the best way to use PSAV and confused the issue of its utility in the early detection setting. Studies of disease prognosis suggest that PSAV is strongly associated with lethal cancers. However, prospective screening trials find that PSAV is at best a weak predictor of high-risk disease. In this commentary, we synthesize and reconcile the evidence about the value of PSAV in the early detection setting. We review recent studies of PSAV and determine a set of statistical considerations that we believe to be critical in study evaluation and interpretation. We explain why the association between PSAV and disease-specific survival does not necessarily imply that PSAV will be a useful screening tool. In addition, we argue that the standard concept of PSAV - the absolute change in PSA per year - confuses disease aggressiveness with the interval from disease onset to detection. We therefore recommend that other methods be explored to incorporate information about PSA kinetics that could ultimately improve - and even transform - how we detect and treat prostate cancer.

Original languageEnglish (US)
Pages (from-to)1510-1515
Number of pages6
JournalJournal of the National Cancer Institute
Volume99
Issue number20
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Early Detection of Cancer
Prostatic Neoplasms
Uncertainty
Publications

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. / Etzioni, Ruth; Ankerst, Donna P.; Weiss, Noel S.; Inoue, Lurdes Y.T.; Thompson, Ian M.

In: Journal of the National Cancer Institute, Vol. 99, No. 20, 01.10.2007, p. 1510-1515.

Research output: Contribution to journalComment/debate

Etzioni, Ruth ; Ankerst, Donna P. ; Weiss, Noel S. ; Inoue, Lurdes Y.T. ; Thompson, Ian M. / Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. In: Journal of the National Cancer Institute. 2007 ; Vol. 99, No. 20. pp. 1510-1515.
@article{c45e0528854244c8b3980e0343e5f9f9,
title = "Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence",
abstract = "Prostate-specific antigen velocity (PSAV) is one of the oldest concepts in PSA screening, yet today it is one of the most controversial. Publication of a wide range of studies with different designs, study populations, and results has fueled uncertainty about the best way to use PSAV and confused the issue of its utility in the early detection setting. Studies of disease prognosis suggest that PSAV is strongly associated with lethal cancers. However, prospective screening trials find that PSAV is at best a weak predictor of high-risk disease. In this commentary, we synthesize and reconcile the evidence about the value of PSAV in the early detection setting. We review recent studies of PSAV and determine a set of statistical considerations that we believe to be critical in study evaluation and interpretation. We explain why the association between PSAV and disease-specific survival does not necessarily imply that PSAV will be a useful screening tool. In addition, we argue that the standard concept of PSAV - the absolute change in PSA per year - confuses disease aggressiveness with the interval from disease onset to detection. We therefore recommend that other methods be explored to incorporate information about PSA kinetics that could ultimately improve - and even transform - how we detect and treat prostate cancer.",
author = "Ruth Etzioni and Ankerst, {Donna P.} and Weiss, {Noel S.} and Inoue, {Lurdes Y.T.} and Thompson, {Ian M.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1093/jnci/djm171",
language = "English (US)",
volume = "99",
pages = "1510--1515",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "20",

}

TY - JOUR

T1 - Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence

AU - Etzioni, Ruth

AU - Ankerst, Donna P.

AU - Weiss, Noel S.

AU - Inoue, Lurdes Y.T.

AU - Thompson, Ian M.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Prostate-specific antigen velocity (PSAV) is one of the oldest concepts in PSA screening, yet today it is one of the most controversial. Publication of a wide range of studies with different designs, study populations, and results has fueled uncertainty about the best way to use PSAV and confused the issue of its utility in the early detection setting. Studies of disease prognosis suggest that PSAV is strongly associated with lethal cancers. However, prospective screening trials find that PSAV is at best a weak predictor of high-risk disease. In this commentary, we synthesize and reconcile the evidence about the value of PSAV in the early detection setting. We review recent studies of PSAV and determine a set of statistical considerations that we believe to be critical in study evaluation and interpretation. We explain why the association between PSAV and disease-specific survival does not necessarily imply that PSAV will be a useful screening tool. In addition, we argue that the standard concept of PSAV - the absolute change in PSA per year - confuses disease aggressiveness with the interval from disease onset to detection. We therefore recommend that other methods be explored to incorporate information about PSA kinetics that could ultimately improve - and even transform - how we detect and treat prostate cancer.

AB - Prostate-specific antigen velocity (PSAV) is one of the oldest concepts in PSA screening, yet today it is one of the most controversial. Publication of a wide range of studies with different designs, study populations, and results has fueled uncertainty about the best way to use PSAV and confused the issue of its utility in the early detection setting. Studies of disease prognosis suggest that PSAV is strongly associated with lethal cancers. However, prospective screening trials find that PSAV is at best a weak predictor of high-risk disease. In this commentary, we synthesize and reconcile the evidence about the value of PSAV in the early detection setting. We review recent studies of PSAV and determine a set of statistical considerations that we believe to be critical in study evaluation and interpretation. We explain why the association between PSAV and disease-specific survival does not necessarily imply that PSAV will be a useful screening tool. In addition, we argue that the standard concept of PSAV - the absolute change in PSA per year - confuses disease aggressiveness with the interval from disease onset to detection. We therefore recommend that other methods be explored to incorporate information about PSA kinetics that could ultimately improve - and even transform - how we detect and treat prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=35548948941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548948941&partnerID=8YFLogxK

U2 - 10.1093/jnci/djm171

DO - 10.1093/jnci/djm171

M3 - Comment/debate

C2 - 17925534

AN - SCOPUS:35548948941

VL - 99

SP - 1510

EP - 1515

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 20

ER -